Search Results
Your search for 3 matches 15291 pages
Showing 851 - 900Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer
In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phase III ALEXANDRA/IMpassion030 trial. The results were presented at the 2024 European Breast Cancer...
Addition of Oxaliplatin to Fluoropyrimidine/Bevacizumab in Initial Therapy for Metastatic Colorectal Cancer in Older Patients
In a Japanese phase III trial (JCOG1018) reported in the Journal of Clinical Oncology, Takashima et al found that adding oxaliplatin to fluoropyrimidine/bevacizumab did not improve progression-free survival in the initial treatment of older patients with unresectable metastatic colorectal cancer....
Sacituzumab Govitecan in Cisplatin-Ineligible Advanced Urothelial Cancer After ICI Therapy
In cohort 2 of the phase II TROPHY-U-01 study, reported in the Journal of Clinical Oncology, Petrylak et al found that sacituzumab govitecan-hziy was active in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer progressing after immune checkpoint inhibitor (ICI)...
Fam-Trastuzumab Deruxtecan-nxki in Unresectable or Metastatic HER2-Positive Solid Tumors
On April 5, 2024, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted accelerated approval for adults with unresectable or metastatic HER2-positive (immunohistochemistry 3+) solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.1 Supporting...
Nivolumab in Combination With Cisplatin Plus Gemcitabine in Treatment of Unresectable or Metastatic Urothelial Carcinoma
Nivolumab (Opdivo) was approved for use in combination with cisplatin and gemcitabine for first-line treatment of patients with unresectable or metastatic urothelial carcinoma.1 Supporting Efficacy Data Approval was based on the open-label CheckMate 901 trial (ClinicalTrials.gov identifier...
New Collaborative Guideline Highlights the Importance of Multidisciplinary Care for Patients With Osteoradionecrosis
A joint guideline from the International Society of Oral Oncology–Multinational Association for Supportive Care in Cancer and ASCO seeks to fill a gap in the clinical guidance for patients with head and neck cancers who develop osteoradionecrosis following their head and neck radiation therapy.1...
Nivolumab Plus Chemotherapy Extends Survival in Lymph Node–Only Metastatic Urothelial Cancer
The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of...
Chinese Study Finds Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer
Nasopharyngeal carcinoma is an aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is less than 1 per 100,000 in Europe, the United States, and the Pacific,1 data from the International Agency...
Belzutifan vs Everolimus in Previously Treated Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Choueiri and colleagues, the phase III LITESPARK-005 trial has shown improved progression-free survival with the hypoxia-inducible factor–2α inhibitor belzutifan vs everolimus in previously treated patients with advanced clear-cell renal cell...
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...
Prescription for Progress: Lancet Oncology Commission’s Practical Strategies for Global Cancer Surgery
In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...
T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy
In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In...
Adjuvant Pembrolizumab vs Placebo in Stage III Melanoma: Long-Term Health-Related Quality of Life
In an analysis from the phase III EORTC 1325-MG/KEYNOTE-054 trial reported in The Lancet Oncology, Bührer et al found that adjuvant pembrolizumab was not associated with significant differences in long-term health-related quality of life (HRQOL) compared with placebo in patients with stage III...
What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024...
Ruxolitinib for Corticosteroid-Refractory Sclerotic Chronic GVHD
In a phase II study reported in the Journal of Clinical Oncology, Vijaya Raj Bhatt, MS, MBBS, and colleagues found that ruxolitinib produced responses in patients with corticosteroid-refractory sclerotic chronic graft-vs-host disease (GVHD) after transplantation for hematologic malignancies. Study ...
ICI-Based Strategies in Advanced, Progressing EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhao et al, meta-analyses of trials of immune checkpoint inhibitors (ICIs) in patients with advanced EGFR-mutated non–small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitor (TKI) treatment indicate that the optimal treatment strategy is...
Previously Untreated Cancer of Unknown Primary: Site-Specific Therapy Guided by a 90-Gene Expression Assay
In a Chinese single-center trial (Fudan CUP-001) reported in The Lancet Oncology, Liu et al found that site-specific therapy guided by a 90-gene expression assay improved progression-free survival vs empirical chemotherapy in previously untreated patients with cancer of unknown primary (CUP) who...
Many Women Unaware of Preventive Benefits of Diet for Breast Cancer Risk
Just 28% of U.S. women may be aware that a healthful diet can lower the risk of developing breast cancer, according to a recent survey conducted by the Physicians Committee for Responsible Medicine and Morning Consult. Background The Physicians Committee for Responsible Medicine is a national...
Adjuvant Everolimus in Localized Papillary and Chromophobe Non–Clear Cell Renal Cell Carcinoma
In a subgroup analysis of the EVEREST trial reported in JAMA Network Open, Gulati et al found that adjuvant everolimus did not improve recurrence-free survival vs placebo in patients with localized papillary or chromophobe non–clear cell renal cell carcinoma (RCC). Study Details In the trial,...
Cancer Has Robbed Me of My Fertility and My Olympic Dreams
I was a track and field athlete throughout college, and my goal was to try out for the Olympics, but cancer had other plans for me. In 2010, while in my senior year in college, I began having sharp, shooting pains in my shoulders, which I initially attributed to overzealous training. But the pain...
Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer
Olaparib may be effective in treating men with biochemically recurrent prostate cancer without accompanying hormone therapy, according to a novel study published by Marshall et al in JAMA Oncology. Background Although most men with localized prostate cancer can be cured with surgery or primary...
Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, 2024, ponatinib (Iclusig) was granted accelerated approval for use with chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL).1 Ponatinib is a multitargeted kinase inhibitor. Supporting Efficacy Data and How It Is Used Approval ...
Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, the anti-CD22 monoclonal antibody inotuzumab ozogamicin (Besponsa), which is bound to a toxic natural calicheamicin, was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting...
CAR T-Cell Therapy in Refractory Follicular Lymphoma
On May 15, 2024, lisocabtagene maraleucel (Breyanzi) was granted accelerated approval for adults with relapsed or refractory follicular lymphoma with two or more prior lines of systemic therapy.1 The agent is a CD19-directed genetically modified autologous T-cell immunotherapy. Supporting Efficacy...
Hypofractionated vs Conventionally Fractionated Radiation After Implant-Based Breast Reconstruction
In a trial reported in JAMA Oncology, Julia S. Wong, MD, and colleagues found that hypofractionated postmastectomy radiation therapy did not improve outcomes in the physical well-being domain of the Functional Assessment of Cancer Therapy–Breast (FACT-B) assessment vs conventionally fractionated...
Disparities in Exposure to Tobacco Content on Streaming Platforms
The risk of encountering tobacco products being advertised, marketed, or promoted on streaming services based on race, ethnicity, socioeconomic status, and smoking habits was identified in a recent study published by Onyeaka et al in JAMA Network Open. Background The World Health Organization...
Early Interventions May Improve Long-Term Academic Achievement in Pediatric Brain Tumor Survivors
Investigators have found that providing early developmental resources may help reduce the adverse effects of brain tumors and cancer therapy on the academic achievement of young pediatric cancer survivors, according to a recent study published by Somekh et al in the Journal of the National Cancer...
Inoperable Stage III NSCLC: Adaptive Radiotherapy Based on FDG-PET Tumor Residual Uptake
In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard...
BTK Degraders and CELMoDs: Novel Mechanisms Overcoming Resistance in Hematologic Malignancies
Despite advances in targeted therapies for hematologic malignancies, drug resistance and persistent side effects continue to challenge clinicians and limit patient outcomes, underscoring the urgent need for novel therapeutic approaches. At the 2024 Pan Pacific Lymphoma Conference, Marc S. Hoffmann, ...
Menin Inhibitor in KMT2A-Rearranged Relapsed or Refractory Acute Leukemia
In a phase I/II study (AUGMENT-101) reported in the Journal of Clinical Oncology, Issa et al found that revumenib, an oral small-molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, was active in patients with KMT2A-rearranged (KMT2A) relapsed or refractory acute...
Advanced Biliary Tract Cancers: Bevacizumab/Erlotinib Maintenance vs Active Surveillance
In an Indian phase II trial (BEER BTC) reported in the Journal of Clinical Oncology, Ramaswamy et al found that maintenance therapy with bevacizumab/erlotinib improved progression-free survival vs active surveillance in patients with advanced biliary tract cancers who had at least stable disease...
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the...
AI May Help Uncover Relationship Between Radiation Therapy for NSCLC and Cardiac Arrhythmia
Artificial intelligence (AI) tools may be used to better understand the risk of specific cardiac arrhythmias when various parts of the heart are exposed to different thresholds of radiation as part of a treatment plan for non–small cell lung cancer (NSCLC), according to a recent study published by...
Metastatic Pancreatic Adenocarcinoma: Addition of Devimistat to mFFX
As reported in the Journal of Clinical Oncology, Philip et al found that the phase III AVENGER 500 study showed no overall survival benefit with devimistat plus modified fluorouracil, oxaliplatin, irinotecan, and leucovorin (mFFX) vs FFX in patients with metastatic pancreatic adenocarcinoma. As...
Acalabrutinib Plus Chemoimmunotherapy Improves Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Combining Bruton’s tyrosine kinase (BTK) inhibition with chemoimmunotherapy induction significantly extended progression-free survival for older patients with mantle cell lymphoma, and there was also a trend toward improvement on the overall survival benefit, according to data presented during the...
ASCO Guideline Update Highlights the Importance of Early Integration of Palliative Care for Patients With Cancer
Growing awareness of the benefits of palliative care in patients with cancer has prompted ASCO to update its recommendations for clinicians, patients, caregivers, and health-care organizations on integrating palliative care in oncology.1 The updated guideline reinforces prior recommendations in the ...
Exercise Program May Improve Symptoms, Quality of Life in Patients With Metastatic Breast Cancer
Researchers have shown that participating in an exercise program may improve pain, fatigue, and the quality of life in patients with metastatic breast cancer, according to a recent study published by Hiensch et al in Nature Medicine. Background “Although there’s substantial evidence for the...
An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate
At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emerging field of cardio-oncology is blazing a path toward “bigger and bolder cancer care” and offered...
LIBRETTO-431 Trial Shows Selpercatinib Is Effective in East Asian Patients With RET Fusion–Positive Non–Small Cell Lung Cancer
A subgroup analysis of data from the LIBRETTO-431 trial (ClinicalTrials.gov identifier NCT04194944) showed that the selective RET inhibitor selpercatinib safely improved progression-free survival compared to chemotherapy plus pembrolizumab in East Asian patients diagnosed with RET fusion–positive...
Detecting Residual Disease After Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
Although esophageal cancer in the United States is relatively rare, affecting about 22,400 people each year and making up about 1% of all cancer cases,1 the disease is common in East and Central Asia countries. Nearly 90% of patients with esophageal cancer in Asia are diagnosed with the squamous...
Gift of Truth: Reflections on a Father’s Cancer Journey
It was a hot and humid Tuesday in July, and I distinctly remember being grateful for the air conditioning in the pastel-shaded waiting room of the oncology outpatient clinic. My father sat silently beside me. We knew this room well, as we did the doctor we had arrived to see. He had been my...
Age Is Just a Number: Treatment Considerations for Endometrial Cancer in Older Women
Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...
What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored by two speakers at the 2024 Pan Pacific Lymphoma Conference, sponsored by the University of...
FDA Approves Neoadjuvant/Adjuvant Durvalumab for Resectable NSCLC
The U.S. Food and Drug Administration (FDA) has approved the PD-L1 inhibitor durvalumab (Imfinzi) with platinum-containing chemotherapy as neoadjuvant treatment followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive)...
Mouthwash-Based Test May Help Predict Head and Neck Cancer Recurrence
Researchers have examined whether a mouthwash-based test could detect biomarkers to help physicians predict disease recurrence in patients with head and neck cancer, according to a recent study published by Franzmann et al in JAMA Otolaryngology–Head & Neck Surgery. Background Head and neck...
Recurrent or Advanced Endometrial Cancer: Atezolizumab Plus Chemotherapy
As reported in The Lancet Oncology by Nicoletta Colombo, MD, and colleagues, the phase III AtTEnd trial showed improved progression-free survival with the addition of atezolizumab to chemotherapy in patients with recurrent or advanced endometrial cancer, particularly among those with mismatch...
Completion Axillary Lymph Node Dissection to Select Adjuvant Treatment in Breast Cancer and Associated Impairment of Arm Function
In an analysis involving the phase III SENOMAC trial reported in The Lancet Oncology, de Boniface et al found that the use of completion axillary lymph node dissection (cALND) to identify pN2-3 status (at least four nodal metastases) in patients with breast cancer, and thus qualification for...
Efficacy of ‘Symptom-Triggered Testing’ for Detection of Ovarian Cancer
“Symptom-triggered testing”—prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat—detected early-stage aggressive ovarian cancer in one of four individuals affected, according to an analysis from the ROCkeTS trial published by Kwong et al in the ...
Combination Immunotherapies May Boost T-Cell Responses in Patients With Melanoma
Researchers may have uncovered how combination immunotherapies targeting the immune checkpoints PD-1 and LAG-3 may work together to activate immune responses in patients with melanoma, according to two recent studies published by Cillo et al and Andrews et al in Cell. The findings may shed light on ...
Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?
With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop treatment and remain in remission. “Stopping tyrosine kinase inhibitor therapy is something we get a...
